| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on October 4, 2023.
Each company will hold its respective Special Meeting of Stockholders virtually at 12 p.m. ET (10:00 a.m. MT / 9:00 a.m. PT) on Thursday, January 4, 2024. The stockholders of record as of the close of business on November 29, 2023, will be entitled to vote at their respective Special Meetings of Stockholders.
The merger remains on track to close in the first quarter of 2024, subject to approval by both companies' stockholders and satisfaction of other customary closing conditions.
Standard BioTools stockholders who need assistance voting or have questions regarding the Special Meeting may contact Standard BioTools' proxy solicitor, Alliance Advisors LLC, at (800) 574-5969. SomaLogic stockholders who need assistance voting or have questions regarding the Special Meeting may contact SomaLogic's proxy solicitor, Morrow Sodali LLC, at (800) 662-5200.
Standard BioTools' and SomaLogic's definitive proxy materials regarding the Special Meetings can be found on the Investor Relations page of each company's website at http://investors.standardbio.com and https://investors.somalogic.com.
